Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMVAZ vs LANOXICAPS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Heart failure (NYHA class II-IV) with reduced ejection fraction,Atrial fibrillation (rate control)
Intravenous: 500 mg every 6 hours.
0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Terminal elimination half-life is approximately 5-7 days (120-168 hours) in patients with normal renal function; prolonged in renal impairment, necessitating dose adjustment.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Primarily renal excretion as unchanged drug; minor hepatic metabolism via CYP3A4 and glucuronidation.
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
Digitoxin is primarily excreted via the kidneys (approx. 70-80%) as unchanged drug and metabolites; the remainder undergoes biliary/fecal elimination (approx. 20-30%).
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
Digitoxin is approximately 90-97% bound to serum proteins, primarily albumin.
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Volume of distribution is approximately 0.6 L/kg, indicating extensive tissue binding and distribution; the large Vd reflects accumulation in tissues like myocardium and skeletal muscle.
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
Oral bioavailability is virtually 100% (90-100%) for Lanoxicaps (digitoxin), with consistent absorption from the gastrointestinal tract.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
For e GFR <50 m L/min, reduce dose by 50% or extend dosing interval: e GFR 35-50 m L/min: 0.125 mg every 24-48 hours; e GFR 10-34 m L/min: 0.125 mg every 48-72 hours; e GFR <10 m L/min: 0.125 mg every 72-96 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Severe hepatic impairment (Child-Pugh class C) requires dose reduction by 50-75%; monitor digoxin levels. Avoid in fulminant hepatitis.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Neonates: 4-6 mcg/kg/day; Infants: 6-10 mcg/kg/day; Children 1-5 years: 10-15 mcg/kg/day; Children 6-12 years: 8-10 mcg/kg/day; Adolescents: 3-5 mcg/kg/day. All doses given orally.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
Start at lower dose (0.0625-0.125 mg daily) due to reduced renal function and lean body mass; monitor serum creatinine and digoxin levels.
None
Toxicity: Narrow therapeutic index; monitor serum levels; avoid in patients with ventricular fibrillation or outflow obstruction.
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Monitor for digitalis toxicity (anorexia, nausea, visual disturbances, arrhythmias). Adjust dose in renal impairment, hypokalemia, hypomagnesemia, hypercalcemia, and hypothyroidism.
None
Ventricular fibrillation,Hypersensitivity to digitalis glycosides,Wolff-Parkinson-White syndrome with atrial fibrillation,Second- or third-degree AV block (without pacemaker),Hypertrophic obstructive cardiomyopathy
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
High-fiber foods (bran, oats) and certain foods containing pectin can reduce digoxin absorption; take Lanoxicaps on an empty stomach or at least 1 hour before or 2 hours after meals. St. John's Wort may decrease digoxin levels. Avoid licorice root, which can cause hypokalemia and increase toxicity. Consistent dietary potassium intake is important; avoid potassium supplements unless directed.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
FDA Pregnancy Category C. First trimester: digitalis glycosides cross placenta; animal studies show fetotoxicity, but no adequate human data. Second/third trimester: risk of fetal bradycardia, low birth weight; therapeutic levels near toxic for fetus. Use only if maternal benefit outweighs risk.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
Digoxin is excreted into breast milk at low levels (M/P ratio ~0.6–0.9); infant exposure is subtherapeutic. Considered compatible with breastfeeding, but monitor infant for signs of digoxin toxicity (e.g., arrhythmias, nausea).
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
Increased volume of distribution and renal clearance in pregnancy may lower digoxin levels; dose adjustment often needed in third trimester. Monitor levels frequently and increase dose if subtherapeutic. Postpartum, reduce dose as clearance normalizes.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Lanoxicaps (digoxin) has a high bioavailability (90-100%) compared to standard digoxin tablets; adjust dose when switching formulations to avoid toxicity. Monitor renal function and electrolytes (especially potassium, magnesium, calcium) closely; hypokalemia increases digoxin toxicity risk. Digoxin toxicity can present with arrhythmias (e.g., bidirectional ventricular tachycardia, atrial tachycardia with block) and visual disturbances (yellow-green halos). Use digoxin-specific Fab fragments for life-threatening toxicity. Therapeutic drug monitoring: draw levels at least 6-8 hours after dose; target 0.5-0.9 ng/m L for heart failure, 0.8-2.0 ng/m L for atrial fibrillation.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
Take exactly as prescribed; do not miss doses or double up. If a dose is missed, skip it unless close to next dose.,Do not switch between Lanoxicaps and standard digoxin tablets without your doctor's approval due to different absorption.,Report symptoms of toxicity: nausea, vomiting, diarrhea, confusion, visual changes (blurred vision, yellow-green halos), or irregular heartbeat.,Keep regular appointments for blood tests to monitor digoxin levels, kidney function, and electrolytes.,Avoid over-the-counter medications, especially antacids, kaolin-pectin, and some laxatives, which can affect absorption.,Maintain consistent dietary intake of potassium-rich foods (bananas, oranges) and avoid extreme changes in diet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMVAZ vs LANOXICAPS, answered by our medical review team.
AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. LANOXICAPS is a Cardiac Glycoside that works by Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMVAZ and LANOXICAPS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. The standard adult dose of LANOXICAPS is: 0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMVAZ and LANOXICAPS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. LANOXICAPS is classified as Category C. FDA Pregnancy Category C. First trimester: digitalis glycosides cross placenta; animal studies show fetotoxicity, but no adequate human data. Second/third trimester: risk of fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.